Trial reportThe Journal of antimicrobial chemotherapy2009
Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women.
Trial report in The Journal of antimicrobial chemotherapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 33 citations in OpenAlex.
- Population pharmacokinetics of nevirapine in Malaysian HIV patients: a non-parametric approach.European journal of clinical pharmacology · 2016Trial
- Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission.The Journal of infectious diseases · 2013Trial
- Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum.Journal of acquired immune deficiency syndromes (1999) · 2012Trial
- Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients.Antimicrobial agents and chemotherapy · 2010Trial
- The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children.British journal of clinical pharmacology · 2016Article
- Article
- Low level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphism.Infection · 2014Article
- Obstetric Pharmacokinetic Dosing Studies are Urgently Needed.Frontiers in pediatrics · 2014Review
- Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state.Antimicrobial agents and chemotherapy · 2013Article
- Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians.Pharmacogenetics and genomics · 2012Article
- Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.British journal of clinical pharmacology · 2012Article
- Pharmacokinetic optimization of antiretroviral therapy in pregnancy.Clinical pharmacokinetics · 2012Review
- Clinical perspectives on human genetic screening to prevent nevirapine toxicity.Personalized medicine · 2012Article
- Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians.Pharmacogenomics · 2012Article
- Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent.AIDS (London, England) · 2011Article
- Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults.AIDS research and therapy · 2010Article
- Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases.HIV clinical trialsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 2 countries.
Funding
Abstract
objectivesTo investigate the association of single nucleotide polymorphisms (SNPs) with nevirapine concentrations following intra-partum single-dose nevirapine.
methodsPlasma and DNA samples were obtained from 330 HIV-infected Thai women who received intra-partum single-dose nevirapine in the PHPT-2 clinical trial to prevent perinatal HIV transmission. Nine SNPs within CYP2B6, CYP3A4 and ABCB1 were genotyped by real-time PCR. Nevirapine plasma concentrations were determined by HPLC and used in a population pharmacokinetic analysis.
resultsHigher nevirapine exposure was observed in women carrying the CYP2B6 516G>T polymorphism, but this did not reach statistical significance (P = 0.054). The TGATC CYP2B6 haplotype (g.3003T, 516G, 785A, g.18492T and g.21563C) was associated with increased nevirapine clearance and lower exposure (P = 0.0029). The median time for nevirapine concentrations to reach 10 ng/mL post-partum (nevirapine IC(50) for HIV-1) was 14 days [interquartile range (IQR, 14-18)] for TGATC homozygotes, 16 days (14-20) for TGATC heterozygotes and 18 days (14-20) for non-TGATC homozygotes (P = 0.020).
conclusionsThe CYP2B6 516G>T impact on nevirapine concentrations was less pronounced after intra-partum single-dose nevirapine than reported under steady-state conditions, perhaps due to lack of enzyme auto-induction at the time of dosing. Although the TGATC CYP2B6 haplotype may shorten the persistence of nevirapine post-partum, its practical implications for the prevention of HIV transmission or selection of resistance mutations are likely limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.